CanBas Co., Ltd. (4575) AI Stock Analysis

• Market Cap: ¥22.26B
• Dividend Yield: N/A
• Average Volume (3M): 998.18K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.76
• Revenue Growth: N/A
• EPS Growth: 9.48%
• Country: JP
• Employees: 11
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -16.87
• Shares Outstanding: 19,713,655
• 10 Day Avg. Volume: 264,820
• 30 Day Avg. Volume: 998,180
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 32 Underperform
• Price Target: ―

CanBas Co., Ltd. is facing substantial financial difficulties due to its inability to generate revenue, leading to negative profitability metrics. The technical indicators suggest a bearish trend, and the valuation metrics are unattractive, with a negative P/E ratio and no dividend yield. The strong balance sheet with no debt is a positive, but it does not outweigh the significant operational challenges.

CanBas Co., Ltd. Business Overview & Revenue Model

Company Description

CanBas Co., Ltd., a clinical stage biopharmaceutical company, develops therapeutics for cancer patients. It develops CBP501, a calmodulin-modulating peptide to treat various cancer; and CBS9106, a reversible exportin-1inhibitor that is in Phase I clinical trial for the treatment of solid tumors. The company has a collaboration alliance with Stemline Therapeutics, Inc. CanBas Co., Ltd. was incorporated in 2000 and is based in Numazu, Japan.

How the Company Makes Money

CanBas Co., Ltd. generates revenue primarily through the successful development and commercialization of its pharmaceutical products and technologies. The company invests in research and development to create proprietary drugs, which it can then license to larger pharmaceutical companies or bring to market itself. Revenue streams include milestone payments from licensing agreements, royalties from drug sales, and potentially direct sales of its pharmaceutical products. Additionally, strategic partnerships and collaborations with other biotech or pharmaceutical firms play a crucial role in its revenue model, providing both financial support and access to broader markets for its developed therapies.

CanBas Co., Ltd. Financial Statement Overview

Summary

CanBas Co., Ltd. faces significant challenges with no revenue or profit generation, heavily relying on equity financing. The absence of revenue growth and negative cash flows from operations are critical concerns, despite a strong balance sheet without debt.

Income Statement

CanBas Co., Ltd. shows a significant decline in financial performance with zero revenue over recent periods, leading to negative gross profit and net income. The company's inability to generate revenue is a major concern, with continuous negative EBIT and EBITDA margins indicating operational inefficiencies.

Balance Sheet

The balance sheet reflects a strong equity position and no debt, which is a positive sign of financial stability. However, the lack of revenue generation limits the company's growth potential, and the high equity ratio indicates reliance on shareholder equity without leveraging debt.

Cash Flow

Cash flow statements reveal negative operating and free cash flows, highlighting challenges in generating cash from operations. The company's cash position is strong due to financing activities, but sustainable cash generation from operations is missing, posing a long-term risk.

Breakdown	TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	108.94M	110.00M
Gross Profit	-1.56B	-984.00M	-671.00M	-608.00M	-322.00M	-332.00M
EBITDA	-1.49B	53.65M	-1.28B	-848.65M	-522.28M	-566.54M
Net Income	-1.49B	-1.21B	-1.24B	-855.58M	-531.03M	-572.79M
Balance Sheet
Total Assets	2.83B	2.43B	2.09B	790.71M	1.30B	1.26B
Cash, Cash Equivalents and Short-Term Investments	2.60B	1.89B	1.62B	737.77M	1.15B	1.11B
Total Debt	0.00	0.00	0.00	367.34M	749.99M	749.99M
Total Liabilities	155.65M	91.99M	153.85M	540.02M	857.64M	1.03B
Stockholders Equity	2.67B	2.34B	1.93B	250.69M	437.97M	236.90M
Cash Flow
Free Cash Flow	0.00	-1.28B	-1.40B	-719.81M	-688.57M	-552.92M
Operating Cash Flow	0.00	-1.28B	-1.40B	-719.81M	-688.57M	-552.92M
Investing Cash Flow	0.00	0.00	0.00	182.00K	0.00	-72.00K
Financing Cash Flow	0.00	1.54B	2.27B	282.75M	728.80M	901.66M

CanBas Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1175.00
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4575, the sentiment is Neutral. The current price of 1175 is below the 20-day moving average (MA) of 1223.05, above the 50-day MA of 1139.12, and above the 200-day MA of 1016.29, indicating a neutral trend. The MACD of 2.50 indicates Positive momentum. The RSI at 44.34 is Neutral, neither overbought nor oversold. The STOCH value of 19.48 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4575.

CanBas Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4584	55 Neutral	¥13.78B	40.67	―	―	120.34%	―
4592	48 Neutral	¥178.99B	-49.11	―	―	―	-58.12%
4579	47 Neutral	¥14.19B	-24.80	-8.37%	―	40.66%	24.86%
4563	44 Neutral	¥32.04B	-0.83	-1304.33%	―	58.24%	-234.81%
4571	40 Underperform	¥9.79B	-10.90	―	―	51.72%	-34.93%
4575	32 Underperform	¥22.26B	―	―	―	―	9.48%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%